First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2015.1115641

First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol
, Guido Kroemer
, Lorenzo Galluzzi

Institut national de la santé et de la recherche médicale
Université Paris Descartes
Sorbonne Université
Centre de Recherche des Cordeliers
Université Paris-Sud
Assistance publique – Hôpitaux de Paris
Karolinska Institutet

Research output: Contribution to journal › Editorial

323 Scopus citations

Abstract

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX^GM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

Original language	English
Article number	e1115641
Journal	Oncoimmunology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2015.1115641
State	Published - 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Granulocyte macrophage colony-stimulating factor
Imlygic®
OPTiM
OncoVEX
T-vec
talimogene laherparepvec

Access to Document

10.1080/2162402X.2015.1115641

Cite this

@article{c19c2800f35e43709ae8bddd684fdb9c,

title = "First oncolytic virus approved for melanoma immunotherapy",

abstract = "On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic{\textregistered}) becomes therefore the first oncolytic virus approved for cancer therapy in the US.",

keywords = "Granulocyte macrophage colony-stimulating factor, Imlygic{\textregistered}, OPTiM, OncoVEX, T-vec, talimogene laherparepvec",

author = "Jonathan Pol and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2016, Taylor \& Francis Group, LLC.",

year = "2016",

doi = "10.1080/2162402X.2015.1115641",

language = "English",

volume = "5",

journal = "Oncoimmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - First oncolytic virus approved for melanoma immunotherapy

AU - Pol, Jonathan

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2016

Y1 - 2016

N2 - On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

AB - On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

KW - Granulocyte macrophage colony-stimulating factor

KW - Imlygic®

KW - OPTiM

KW - OncoVEX

KW - T-vec

KW - talimogene laherparepvec

UR - https://www.scopus.com/pages/publications/85046155009

U2 - 10.1080/2162402X.2015.1115641

DO - 10.1080/2162402X.2015.1115641

M3 - Editorial

AN - SCOPUS:85046155009

SN - 2162-4011

VL - 5

JO - Oncoimmunology

JF - Oncoimmunology

IS - 1

M1 - e1115641

ER -

First oncolytic virus approved for melanoma immunotherapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this